TABLE 2.
Herbal medicine | Object of study | Cohort description | Sample type | Outcome characteristics | References |
---|---|---|---|---|---|
Curcumin | APPswe/PS1dE9 double transgenic mice | Administration of curcumin for 6 months to the HDC, MDC and LDC with diferent dose-level as 400 mg/kg/day, 200 mg/kg/day, 100 mg/kg/day | Hippocampus tissues | PI3K, p-PI3K, AKT, p-AKT↑; IR, IRS-1↓ | Feng et al. |
Curcumin | APPswe/PS1dE9 double transgenic mice | treated with different dose-level as 100 mg/kg/day, 200 mg/kg/day, 400 mg/kg/day. In the positive control group, 10 mg/kg/day RSG was used for treatment. | Hippocampus tissues | Cerebral glucose uptake, IGF-1R, IRS-2, PI3K, p-PI3K, Akt, p-Akt↑; IR, IRS-1↓ | Wang et al. |
Curcumin | Male Wistar rats | orally with curcumin, zinc sulfate, two doses of CurNP and ZnONP, as well as metformin, for 6 weeks. | Hippocampus tissues and blood sample | Aβ, p-tau, redox, inflammation, MAPK/ERK pathway↓ | Abdulmalek et al. |
Quercetin | The human intestinal epithelial cell line Caco-2 | Caco-2 cells were incubated in INDO for 20 min | Mitochondria | Mitochondria dysfunction, oxidative stress↓ | Carrasco-Pozo et al. |
Resveratrol | Male C57BL/6J mice | HFD mice were treated with/without MET (250 mg/kg/day), RESV (100 mg/kg/day), or COMBO (MET: 250 mg/kg/day, RESV: 100 mg/kg/day) for 5 weeks. | The center and right prefrontal cortex and hippocampus samples | Autophagy↑; BDNF, synaptophysin↓ | Yang et al. |
Resveratrol | The Zucker diabetic fatty (ZDF) rat model | ZDF rats and their LN were dosed with a SGP Mixture consisting of grape seed extract, concord grape juice and RES by oral gavage for 10 days | Plasma, urine and brain tissues | The bioavailability of resveratrol, the level of resveratrol in the brain↓ | Chen et al. |
BBR | Male wistar rats and N2a cells | STZ-treated groups include DM, BBr, and Met were fed with high sugar and fat diet until the time for sacrifice. | N2a cell samples and hippocampal tissue | Glucose utilization, PI3k/PGC epsilon pathway↑; Aβ, AD-related neuronal damage↓ | Wu et al. |
BBR | Chinese hamster ovary (CHO) cells | CHO-APP695 cells were treated with BBR, PIO or a combination of BBR + PIO. Microglial cells were pre-treated with different concentrations of BBR, ranging from 0.3 to 10 μM and incubated for 2 h at 37°C. | Cell samples | basal respiration, pro-inflammatory cytokines in activated microglial cells↓ | Wong et al. |
BBR | A STZ diabetes rat model feeding with a high-fat diet | Metformin group with intragastrically administrated 0.18 g/kg of metformin hydrochloride and berberine group with intragastrically administrated 150 mg/kg of berberine once a day for 4 weeks. | Serum samples and hippocampus tissues | Cognitive function↑; IR, tau, neuronal apoptosis↓ | Zhang et al. |
BBR | Male Wistar rats | 187.75 mg/kg/d of BBR for BBR group and 184 mg/kg/d of metformin for Met group | Brain tissues | IR, PI3K/Akt/mTOR, MAPK signaling pathways↓ | Chen et al. |
BBR | Male Sprague–Dawley rats | Alzheimer diabetic rats treated with BBR in a dose of 150 mg/kg and with metformin in dose of 540 mg/kg | Hippocampus tissues and blood samples | Endoplasmic reticulum (ER) stress, memory deficits↓ | Xuan et al. |
Extracts of P. harmala | Adult male Wistar rats | Normal rats in group III received daily i.p saline for 2 weeks followed by daily doses of P. harmala per se (187.5 mg/kg; p.o) for 4 weeks, lCl3-exposed rats in group IV were treated with the oral doses of P. harmala 30 min after each neurotoxin injection for a period of 4 weeks, starting from the 15th day of AlCl3 injection | Brain tissues | Aβ, p-tau, GSK3β↓ | Saleh et al. |
Hup A | HFD obese male C57 BL/6 mice and genetic ob/ob mice | Intragastrically administered 0.1 mg or 0.3 mg Hup A per kilogram of body weight per day or vehicle for three mouths. | Brain tissues | insulin, p-Akt↑in high fat-induced mice, but not seen in ob/ob mice | Wang et al. |
Geniposide | Adult male C57BL/6J mice | Treatment groups with low (20 mg/kg, 4 mg/mL in saline) and high (100 mg/kg, 25 mg/mL in saline) by oral administration at the beginning of corticosterone treatment. CREB inhibitor 666–15 (20 mg/kg, 4 mg/mL in saline) was treated to 100 mg/kg geniposide treatment group together by I.P. injection. | Blood samples and hippocampus tissues | CREB↑; cognitive dysfunctions↓ | Sun et al. |
Geniposide | APPswe/PS1dE9 double transgenic AD mice (C57BL/6 background) and primary cortical neurons | Mice: Treated with geniposide (intragastric administration, i.g.) for consecutive 4 weeks at the dose of 5, 10, and 20 mg/kg, respectively. Liraglutide (100lg/kg, i.p.) was used as a positive control. | Blood samples, brain samples, and cell samples | p-Akt↑; P-tau, the phosphorylation of GSK-3β↓ | Zhang et al. |
Cultured cells were incubated with 10 lM geniposide in the presence or absence of insulin (10 lM) for indicated times. | |||||
Geniposide | APPswe/PS1dE9 double transgenic AD mice (C57BL/6 background) and Primary cortical neurons | Mice: Treated with geniposide (intragastric administration, i.g.) for consecutive 4 weeks at the dose of 5, 10, and 20 mg/kg, respectively. Liraglutide (100lg/kg, i.p.) was used as a positive control. | Brain samples and cell samples | BACE1, IDE↑ | Zhang et al. |
Cultured cells were incubated with 10 lM geniposide in the presence or absence of insulin (10 lM) for indicated times. | |||||
Sarsasapogenin | Male Sprague Dawley rats and SH-SY5Y cells | Rats: Treated with the low and high doses of Sar (20 and 60 mg/kg), and positive control insulin (5 U/kg). SH-SY5Y cells: low, middle, and high concentrations of Sar group (HG + Sar, 70 mmol/L glucose +0.1, 1, 10 μmol/L Sar, respectively), and positive control insulin group (HG + In sulin, 70 mmol/L glucose +50 mU/l insulin). | Brain and cell samples | BACE1, Akt/GSK-3β cascade↑; Aβ, p-tau↓ | Zhang et al. |
Asiaticoside | Adult male Sprague-Dawley rats and SH-SY5Y cells | Administered orally with asiaticoside (20 or 40 mg/kg), rosiglitazone (4 mg/kg), or vehicle (10 mL/kg distilled water instead) once daily (9:00 a.m.) for the consecutive 30 days. Pretreatment cells with asiaticoside (0.1, 1 μmol/L) and rosiglitazone (10 μmol/L) for 48 h | Blood samples, brain tissues, and cell samples | Synaptic function↑; cognitive deficits, oxidative stress, PI3K/Akt/NF-κB pathway↓ | Yin et al. |
Ginsenoside Rb1 | C57BL/6N male mice | The ginsenoside Rb1 group (STZ+30 mg/kg ginsenoside Rb1). | Blood samples and brain tissues | Memory and cognitive ability, insulin sensitivity↑; Glucose intolerance↓ | Yang et al. |
Ginsenoside Rg2 | 5XFAD mice and HeLa cell lines | Treated with i.p. Injection of 20 mg/kg Rg2 (or DMSO vehicle) once/day, 5 days/week, for 16 weeks. Age-matched wild-type (WT) male mice were used as a negative control. HeLa cells were treated with using 100 ng/mL tetracycline, or 0.1 mM Rg2 with control or ATG7 siRNA for 48 h. | Blood samples, brain tissues, and cell samples | Cognitive behaviors, autophagy↑ | Fan et al. |
Quercetin | The db/db mice and age-matched wild-type C57BL/6J-db/m mice | db/db + low dosage of quercetin (QL, 35 mg/kg/d, n = 8) and db/db + high dosage of quercetin (QH, 70 mg/kg/d, n = 8). | Brain tissues | Cognition, brain-derived BDNF, Sirtuin type 1↑;insulin, fasting blood glucose↓ | Hu et al. |
Luteolin | Male C57BL/6J mice | The mice were randomized into four groups: Control diet (CD); control diet + luteolin (CDL, luteolin 10 mg/kg); high-fat diet (HFD); high-fat diet + luteolin (HFDL, luteolin 10 mg/kg) | Blood samples and brain tissues | BDNF, synapsin I, postsynaptic density protein 95↑; cognitive impairment, neuroinflammation, oxidative stress, neuronal insulin resistance↓ | Liu et al. |
Piperine | STZ induced rats | control (Vehicle only), diabetic control (STZ only), piperine treated (20 mg/kg day, i.p), and sitagliptin (Positive control) treated. | serum samples, pancreatic and brain tissue samples | Cognition↑; the expression of AD-associated genes↓ | Kumar et al. |
Artemisinin | Wistar rats | Intranasal administration of a single dose of TSP-1-hEDSCs and intraperitoneal administration of artemisinin for 4 weeks. | Blood samples and brain tissues | Aβ, glucose, ROS, TNF-α↓ | Poorgholam et al. |
Mangifera indica Linn extract (MGF) | The leptin receptor KO mouse db/db | 9–12 mice per group (Control = 12, Control-Mangifera indica Linn extract (MGF) = 11, db/db = 10 and db/db-MGF = 9) | Brain tissues and blood samples | Central inflammation, atrophy, body weight, glucose, and insulin levels ↓ | Infante-Garcia et al. |
Lychee seed extract (LSE) | Male Sprague Dawley rats | Treated with normal saline (NS) 1 mL/kg (negative control), donepezil 0.42 mg/kg (positive control), LSE 0.7, 1.4 and 2.8 g/kg by intragastric (IG) administration once a day (daily) at 8 a.m. for 28 consecutive days. | Blood samples and hippocampus tissues | Cognitive functions↑; neuronal injury, glucose, insulin, Aβ, AGEs, tau↓ | Tang et al. |
Yuzu extract | Male Sprague-Dawley rats | AD control, AD yuzu, and control (d 7). | Brain tissues and blood samples | Hippocampal insulin signaling↓ | Yang et al. |
Luteolin, orientin, and isoorientin | RAW 264.7 cells | Treated with 5, 15, and 30 μM of luteolin, orientin, and isoorientin. | Cell samples | Isoorientin: DPPH, NO, and ONOO ↓ | Choi et al. |
Luteolin: ROS, AChE, BChE, BACE1, PTP1B↓ | |||||
Vitexin, isovitexin, and apigenin | RAW 264.7 cells | Treated with various concentrations of vitexin, isovitexin, and apigenin (final concentration; 5, 15, and 30 lM). | Cell samples | Isovitexin: RLAR, HRAR, AGE, AChE, and BChE↓ | Choi et al. |
Vitexin: PTP1B↓ | |||||
Apigenin: NO production, iNOS and COX-2↓ |
Symbol explanation: “↑” means upregulating, increasing, improving and so on. “↓” means downregulating, decreasing, impairing and so on.